|
|
|
| Effect of Qishen Yiqi Dropping Pills on long-term prognosis of patients with chronic heart failure |
| ZHANG Kaixuan1 GENG Wei2 TIAN Xiang2 ZHANG Qi2 ZHAO Can2 YANG Ying2 LI Hua2 |
1.Graduate School, Chengde Medical University, Hebei Province, Chengde 067000, China;
2.Department of Cardiovascular Medicine, the First Central Hospital of Baoding City, Hebei Province, Baoding 071000, China |
|
|
|
Abstract Objective To observe the effect of Qishen Yiqi Dropping Pills on long-term prognosis of patients with chronic heart failure. Methods Four hundred and eleven patients with chronic heart failure were selected from September 2017 to September 2018 in the First Central Hospital of Baoding City in Hebei Province. They were divided into control group (routine treatment, n = 206) and treatment group (routine treatment + Qishen Yiqi Dropping Pills, n = 205) by random number table method. Four weeks was a course of treatment, long-term use, follow-up time was 12-24 months (median follow-up time was 18 months). The levels of NT-proBNP, 6-MWT and LVEF were recorded between two groups before treatment, 6 and 12 months after treatment. Results Finally, 358 patients were included in the evaluation, including 182 cases in control group and 174 cases in treatment group. Overall analysis: there were significant differences in NT-proBNP, LVEF and 6-MWT between two groups with inter group comparison, time point comparison and interaction (P < 0.05). Further intra group comparison: there were significant differences in NT-proBNP, LVEF, 6-MWT between two groups before treatment, 6 and 12 months after treatment with comparison of time points (P < 0.05). Inter group comparison: there were no significant differences in NT-proBNP, LVEF and 6-MWT between two groups before treatment (P > 0.05). 6 and 12 months after treatment, the level of NT-proBNP in treatment group was lower than that in control group, LVEF in treatment group was higher than that in control group, 6-MWT in treatment group was longer than that in control group, the differences were statistically significant (P < 0.05). No serious adverse reactions were found in this study. Conclusion Qishen Yiqi Dropping Pills can obviously improve heart function and exercise tolerance of patients with chronic heart failure. It is worthy of clinical promotion.
|
|
|
|
|
|
[1] 顾东风，黄广勇，吴锡桂，等.中国心力衰竭流行病学调查及其患病率[J].中华心血管病杂志，2003，31（1）：3-6.
[2] Benjamin EJ，Virani SS，Callaway CW，et al. Heart diseaseand stroke statistics-2018 update：a report from the American Heart Association [J]. Circulation，2018，137（12）：E67-E492.
[3] 焦秀清，代升平.芪参益气滴丸治疗慢性心力衰竭的临床观察[J].中国实用医药，2013，8（3）：39-40.
[4] 唐铭翔，颜素岚，周于禄.芪参益气滴丸治疗慢性心力衰竭对容量负荷及疗效的影响[J].中药药理与临床，2017， 33（5）：172-174.
[5] 中华医学会心血管病学分会.2014年中国慢性心力衰竭诊断和治疗指南[J].中华心血管病杂志，2014，42（2）：98-122.
[6] Stewart S，MacIntyre K，Hole DJ，et al. More malignant than cancer? Five-year survival following a first admission for heart failure [J]. Eur J Heart Fail，2001，3（3）：315-322.
[7] Cowie MR，Wood DA，Coats AJS，et al. Survival of patients with a new diagnosis of heart failure：a population based study [J]. Heart，2000，83（5）：505-510.
[8] 程燕，车炜，于晓龙，等.老年心力衰竭患者出院后2年预后及影响因素[J].临床心血管病杂志，2017，33（12）：1206-1209.
[9] 蒋洪强，张金国，谭洪勇，等.黄芪甲苷对慢性心力衰竭大鼠心肌纤维化和结缔组织生长因子表达的影响[J].中国循环杂志，2016，31（2）：165-169.
[10] Lu M，Wang H，Wang J，et al. Astragaloside Ⅳ protects against cardiac hypertrophy via inhibiting the Ca2+/CaN signaling pathway [J]. Planta Med，2014，80（1）：63-69.
[11] Tu L，Pan CS，Wei XH，et al. Astragaloside Ⅳ protects heart from ischemia and reperfusion injury via energy regulation mechanism [J]. Microcirculation，2013，20（8）：736-747.
[12] 周吉燕，樊懿，孔建龙，等.黄芪中不同提取成分对在体大鼠心肌缺血-再灌注损伤的心功能影响[J].中国中药杂志，2000，25（5）：300-302.
[13] Tang LQ，Wei W，Chen LM. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats [J]. J Ethnopharmacol，2006，108（1）：109-115.
[14] 赵岩，杨丹，于珊珊.黄芪甲苷对慢性心力衰竭大鼠心肌细胞凋亡及P-Cx43表达水平的影响[J].临床和实验医学杂志，2018，17（20）：2143-2147.
[15] 马晨，张善飞，曹彦光，等.丹参注射液对离体大鼠心肌能量代谢的调节作用[J].中国药科大学学报，2009，40（2）：147-151.
[16] 周青，何蔚，周俐，等.三七总皂苷对大鼠心肌肥厚的保护作用[J].时珍国医国药，2006，17（4）：506-507.
[17] Yu SM，Cheng ZJ，Kuo SC. Endothelium-dependent relaxation of rat aorta by butein，a novel cyclic AMP-specific phosphodies-terase inhibitor [J]. Eur J Pharmacol，1995，280（1）：69.
[18] 吴刚，吴伦宽.芪参益气滴丸联合常规治疗对慢性心衰临床疗效及心功能指标的影响[J].辽宁中医杂志，2016， 43（6）：1205-1207.
[19] 刘胜强，陈进业，刘发俊，等.芪参益气滴丸对慢性心力衰竭病人心率变异性及心功能的影响[J].中西医结合心脑血管病杂志，2016，14（19）：2221-2223.
[20] 徐志远，谢锋，梁惠玲.慢性心力衰竭患者血清NT-proBNP和cTnI联合检测及临床意义分析[J].中国医药科学，2018，8（1）：241-243.
[21] 高玉军，武会志，于海侠，等.心脏康复治疗对慢性心力衰竭患者NT-proBNP水平和生活质量的影响[J].河北医学，2019，25（9）：1564-1567.
[22] 李传利.NT-proBNP、Hcy、D-二聚体和FIB检测在慢性心力衰竭中的临床价值探讨[J].中国现代医生，2018， 56（29）：129-131.
[23] 卢伟智，赵武民，古勋清，等.慢性心力衰竭患者血浆NT-proBNP的变化及临床意义[J].中华卫生应急电子杂志，2016，2（3）：166-169. |
|
|
|
